Acute exacerbation of chronic obstructive pulmonary disease
Conditions
Interventions
experimental group:bergenin tablet
control group:Placebo
Sponsors
Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Guangdong Medical University
Eligibility
Sex/Gender
All
Age
40 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Male or female aged >= 40 years; 2. Patients that meet the AECOPD diagnostic criteria; 3. Signed and dated written informed consent obtained prior to participation.
Exclusion criteria
Exclusion criteria: 1. Diagnosed with asthma. 2. Complicated with Other respiratory diseases, such as active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, pulmonary fibrosis, pulmonary hypertension, interstitial lung disease, cystic fibrosis, bronchiolitis obliterans. 3. Previous pneumonectomy. 4. Patients with thoracic deformity, pneumothorax, rib fracture, unstable cardiac function (such as recent myocardial infarction, unstable angina) or unstable vital signs. 5. Clinically significant abnormalities shown on chest X-ray or computed tomography scan (if abnormalities were not due to COPD). 6. Abnormal kidney function (serum creatinine >= 2mg/dl or >= 177µmol/l) or abnormal liver function (aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 100U/L). 7. Patients require mechanical ventilation (meeting at least one of the following indications: arterial pH<= 7.25; severe dyspnea and respiratory muscle fatigue or increased work of breathing (use of accessory respiratory muscles, paradoxic abdominal movement, or retraction of intercostal?muscles); heart rate < 50 beats/min and unresponsive; consciousness disorder. 8. Mental disorders. 9. Use antihistamines within 3 days before enrollment. 10. History of allergic diseases. 11. Pregnant and lactating women. 12. Participants who are currently participating in other clinical trials within three months. 13. Antibiotics and expectorants were used 1 day before hospitalization.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| COPD Assessment Test (CAT) score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Inflammation indicators;Lung function;Clinical symptoms of dyspnea and cough;Length of hospitalization; | — |
Countries
China
Contacts
Public ContactDong Wu
Affiliated Hospital of Guangdong Medical University
Outcome results
None listed